The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Open accessAbstract
Checkpoint inhibitors have revolutionized cancer treatment. However, only a minority of patients respond to these immunotherapies. Here, we report that blocking the inhibitory NKG2A receptor enhances tumor immunity by promoting both natural killer (NK) and CD8 + T cell effector functions in mice and humans. Monalizumab, a humanized anti-NKG2A antibody, enhanced NK cell activity against various tumor cells and rescued CD8 + T cell function in combination with PD-x axis blockade. Monalizumab also stimulated NK cell activity against antibody-coated target cells. Interim results of a phase II trial of monalizumab plus cetuximab in previously treated squamous cell carcinoma of the head and neck showed a 31% objective response rate. Most common adverse events were fatigue (17%), pyrexia (13%), and headache (10%). NKG2A targeting with monalizumab is thus a novel checkpoint inhibitory mechanism promoting anti-tumor immunity by enhancing the activity of both T and NK cells, which may complement first-generation immunotherapies against cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., & Moretta, L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.197 · Cited by 1,778
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147
Vermorken, J. B., Trigo, J., Hitt, R., Koralewski, P., Diaz-Rubio, E., Rolland, F., Knecht, R., Amellal, N., Schueler, A., & Baselga, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7447 · Cited by 1,009
Natural killer cells and other innate lymphoid cells in cancer
Chiossone, L., Dumas, P.-Y., Vienne, M., & Vivier, E. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0061-z · Cited by 1,007
Self-citationOkazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 916
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
Targeting natural killer cells and natural killer T cells in cancer
Vivier, E., Ugolini, S., Blaise, D., Chabannon, C., & Brossay, L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3174 · Cited by 850
Self-citationMamessier, E., Sylvain, A., Thibult, M.-L., Houvenaeghel, G., Jacquemier, J., Castellano, R., Gonçalves, A., André, P., Romagné, F., Thibault, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45816 · Cited by 681
Self-citationCD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions
Hashimoto, M., Kamphorst, A. O., Im, S. J., Kissick, H. T., Pillai, R. N., Ramalingam, S. S., Araki, K., & Ahmed, R. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-012017-043208 · Cited by 656
Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics
Paulson, K. G., Park, S. Y., Vandeven, N. A., Lachance, K., Thomas, H., Chapuis, A. G., Harms, K. L., Thompson, J. A., Bhatia, S., Stang, A., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.10.028 · Cited by 528
Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma
Platonova, S., Cherfils-Vicini, J., Damotte, D., Crozet, L., Vieillard, V., Validire, P., André, P., Dieu-Nosjean, M.-C., Alifano, M., Régnard, J.-F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4179 · Cited by 512
Self-citationThe host STING pathway at the interface of cancer and immunity
Corrales, L., McWhirter, S. M., Dubensky, T. W., & Gajewski, T. F. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86892 · Cited by 487
Targeting T Cell Co-receptors for Cancer Therapy
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.023 · Cited by 469
Sagiv-Barfi, I., Kohrt, H. E. K., Czerwinski, D. K., Ng, P. P., Chang, B. Y., & Levy, R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500712112 · Cited by 444
Charych, D. H., Hoch, U., Langowski, J. L., Lee, S. R., Addepalli, M. K., Kirk, P. B., Sheng, D., Liu, X., Sims, P. W., VanderVeen, L. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1631 · Cited by 398
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
Sockolosky, J. T., Trotta, E., Parisi, G., Picton, L., Su, L. L., Le, A. C., Chhabra, A., Silveria, S. L., George, B. M., King, I. C., et al. (2018) · Science · doi:10.1126/science.aar3246 · Cited by 382
Immunoreceptor tyrosine‐based inhibition motifs: a quest in the past and future
Daëron, M., Jaeger, S., Du Pasquier, L., & Vivier, E. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00666.x · Cited by 370
Self-citationNKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines
van Montfoort, N., Borst, L., Korrer, M. J., Sluijter, M., Marijt, K. A., Santegoets, S. J., van Ham, V. J., Ehsan, I., Charoentong, P., André, P., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.028 · Cited by 333
Self-citationIL-21 Induces the Functional Maturation of Murine NK Cells
Brady, J., Hayakawa, Y., Smyth, M. J., & Nutt, S. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2048 · Cited by 303
Le Dréan, E., Vély, F., Olcese, L., Cambiaggi, A., Guia, S., Krystal, G., Gervois, N., Moretta, A., Jotereau, F., & Vivier, E. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199801)28:01<264::aid-immu264>3.0.co;2-o · Cited by 254
Self-citationBenson, D. M., Hofmeister, C. C., Padmanabhan, S., Suvannasankha, A., Jagannath, S., Abonour, R., Bakan, C., Andre, P., Efebera, Y., Tiollier, J., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438028 · Cited by 244
Mingari, M. C., Ponte, M., Bertone, S., Schiavetti, F., Vitale, C., Bellomo, R., Moretta, A., & Moretta, L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1172 · Cited by 241
Vance, R. E., Jamieson, A. M., & Raulet, D. H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.12.1801 · Cited by 238
Class I HLA haplotypes form two schools that educate NK cells in different ways
Horowitz, A., Djaoud, Z., Nemat-Gorgani, N., Blokhuis, J., Hilton, H. G., Béziat, V., Malmberg, K.-J., Norman, P. J., Guethlein, L. A., & Parham, P. (2016) · Science Immunology · doi:10.1126/sciimmunol.aag1672 · Cited by 225
Ferris, R. L., Lenz, H.-J., Trotta, A. M., García-Foncillas, J., Schulten, J., Audhuy, F., Merlano, M., & Milano, G. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.008 · Cited by 190
Targeting NK-cell checkpoints for cancer immunotherapy
Muntasell, A., Ochoa, M. C., Cordeiro, L., Berraondo, P., López-Díaz de Cerio, A., Cabo, M., López-Botet, M., & Melero, I. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.01.003 · Cited by 182
Bertone, S., Schiavetti, F., Bellomo, R. G., Vitale, C., Ponte, M., Moretta, L., & Mingari, M. C. (1999) · European Journal of Immunology · Cited by 181
NK cell recognition of non-classical HLA class I molecules
López-Botet, Llano, M., Navarro, F., & Bellon, T. (2000) · Seminars in Immunology · doi:10.1006/smim.2000.0213 · Cited by 179
McMahon, C. W., Zajac, A. J., Jamieson, A. M., Corral, L., Hammer, G. E., Ahmed, R., & Raulet, D. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.3.1444 · Cited by 162
Rejection versus escape: the tumor MHC dilemma
Garrido, F., Ruiz-Cabello, F., & Aptsiauri, N. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1947-x · Cited by 158
Viant, C., Fenis, A., Chicanne, G., Payrastre, B., Ugolini, S., & Vivier, É. (2014) · Nature Communications · doi:10.1038/ncomms6108 · Cited by 155
Charych, D. H., Khalili, S., Dixit, V., Kirk, P. B., Chang, T., Langowski, J. L., Rubas, W., Doberstein, S. K., Eldon, M. A., Hoch, U., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179431 · Cited by 155
Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells
Ramsuran, V., Naranbhai, V., Horowitz, A., Qi, Y., Martin, M. P., Yuki, Y., Gao, X., Walker-Sperling, V. E. K., Prete, G. Q. D., Schneider, D. K., et al. (2018) · Science · doi:10.1126/science.aam8825 · Cited by 152
Manser, A. R., & Uhrberg, M. (2016) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-015-1750-0 · Cited by 148
Sheu, B., Chiou, S., Lin, H., Chow, S., Huang, S., Ho, H., & Hsu, S.-M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2108 · Cited by 141
NK Cells and Cancer Immunoediting
Guillerey, C., & Smyth, M. J. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_446 · Cited by 110
Yazdi, M. T., van Riet, S., van Schadewijk, A. M., Fiocco, M. F., van Hall, T., Taube, C., Hiemstra, P. S., & van der Burg, S. H. (2015) · Oncotarget · doi:10.18632/oncotarget.6506 · Cited by 105
High-resolution phenotyping identifies NK cell subsets that distinguish healthy children from adults
Mahapatra, S., Mace, E. M., Minard, C. G., Forbes, L. R., Vargas‐Hernández, A., Duryea, T. K., Makedonas, G., Banerjee, P. P., Shearer, W. T., & Orange, J. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181134 · Cited by 77
André, P., Brunet, C., Guia, S., Gallais, H., Sampol, J., Vivier, É., & Dignat‐George, F. (1999) · European Journal of Immunology · Cited by 72
Self-citationLevy, E. M., Sycz, G., Arriaga, J. M., Barrio, M. M., von Euw, E. M., Morales, S. B., Gonzalez, M. S., Mordoh, J., & Bianchini, M. (2009) · Innate Immunity · doi:10.1177/1753425908101404 · Cited by 69
Obinutuzumab: what is there to learn from clinical trials?
Cartron, G., & Watier, H. (2017) · Blood · doi:10.1182/blood-2017-03-771832 · Cited by 68
Expression of CD94–NKG2A inhibitory receptor is restricted to a subset of CD8+ T cells
Braud, V. M., Aldemir, H., Bréart, B., & Ferlin, W. G. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00064-4 · Cited by 65
Development and Function of CD94-Deficient Natural Killer Cells
Orr, M. T., Wu, J., Fang, M., Sigal, L. J., Spee, P., Egebjerg, T., Dissen, E., Fossum, S., Phillips, J. H., & Lanier, L. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015184 · Cited by 54
Segal, N. H., Naidoo, J., Curigliano, G., Patel, S. P., Sahebjam, S., Papadopoulos, K. P., Gordon, M. S., Wang, D., Rueda, A. G., Song, X., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3540 · Cited by 46
Molecular insight into targeting the NK cell immune response to cancer
Rautela, J., Souza-Fonseca-Guimarães, F., Hediyeh-zadeh, S., Delconte, R. B., Davis, M. J., & Huntington, N. D. (2018) · Immunology and Cell Biology · doi:10.1111/imcb.12045 · Cited by 32
Targeting Toll-like receptors against cancer
Du, B., Jiang, Q., Cleveland, J. C., Liu, B., & Zhang, D. (2016) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2016.62 · Cited by 26
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Functional exhaustion of antiviral lymphocytes in COVID-19 patients
Zheng, M., Gao, Y., Wang, G., Song, G., Liu, S., Sun, D., Xu, Y., & Tian, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0402-2 · Cited by 1,768
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
Metadata
- Authors
- André, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., Rossi, B., Remark, R., Breso, V., Bonnet, E., Habif, G., Guia, S., Lalanne, A. I., Hoffmann, C., Lantz, O., Fayette, J., Boyer-Chammard, A., Zerbib, R., Dodion, P., Ghadially, H., Jure-Kunkel, M., Morel, Y., Herbst, R., Narni-Mancinelli, E., Cohen, R. B., & Vivier, E.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 175
- Issue
- 7
- Pages
- 1731-1743.e13
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2902856530
- Cited by
- 1,221
- References
- 51
- FWCI
- 41.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.